Author:
Acar Tayfun,Arvas Melih Besir,Arvas Busra,Ucar Burcu,Sahin Yucel
Abstract
AbstractHydroxychloroquine (HCQ) is a very substantial drug active substance that was approved for emergency use by the FDA during the peak of the COVID-19 pandemic due to its potent antiviral properties. In this study, adsorption and desorption of hydroxychloroquine on sulfur (S)-doped graphene powders were investigated. While the adsorption experiments were carried out in the environment of distilled water (pH 5.0-6.0), HEPES buffer (pH 7.6), and Tris.HCl buffer (pH 8.0) the desorption studies were performed in distilled water. The HCQ adsorbed S-doped graphene powders were characterized by UV-Vis, FT-IR, XRD, BET and TEM techniques. According to UV-Vis measurements, the adsorption efficiency in the HEPES buffer medium at pH 7.6 was the highest (68.72% for H3 (HCQ adsorption with SGr3 graphene in HEPES medium)). FT-IR and XRD analyses confirmed the presence of HCQ on the graphene powders’ surface. While morphological changes on the surfaces of graphene powders were imaged by TEM, BET surface area changes proved the HCQ adsorption. The in vitro toxicity of the developed H3 was found to be lower than that of HCQ alone on the L929 cell line. These fundamental findings of the surface interaction between HCQ and graphene are precious for the design and optimization of a targeted drug based on this molecule and material. The adsorption/desorption features of HCQ onto graphene-based carrier systems which in particular doped with sulfur from functional metals have been investigated for the first time.
Funder
Yıldız Technical University
Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. Ucar, B., Acar, T., Arayici, P.P., Derman, S.: A nanotechnological approach in the current therapy of COVID-19: model drug oseltamivir-phosphate loaded PLGA nanoparticles targeted with spike protein binder peptide of SARS-CoV-2. Nanotechnology 32, 485601 (2021)
2. WHO, The Corona Virus Disease 2019 (COVID-19) (2020) https://www.who.int/emergencies/diseases/novel-coronavirus-2019
3. Liu, J., et al.: Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 6, 1–4 (2020)
4. FDA (2020) FDA Drug Safety Communication: FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. https://www.fda.gov/media/137250/download. Accessed 20 May 2021
5. Bendjeffal. H., Ziati, M., Aloui, A., Mamine, H., Metidji, T., Djebli, A., Bouhedja, Y., : Adsorption and removal of hydroxychloroquine from aqueous media using Algerian kaolin: Full factorial optimisation, kinetic, thermodynamic, and equilibrium studies. Intl J Environ Anal Chem 103, 9, 1–22 (2021)
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献